AIMOVIG is an erenumab injection for preventing migraine in adults. It targets the CGRP receptor, and its device instructions and warning about constipation with serious complications deserve attention alongside the preventive role.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | erenumab-aooe |
| Medicine class | CGRP receptor antagonist monoclonal antibody |
| Forms and strengths | Subcutaneous injection: 70 mg/mL and 140 mg/mL single-dose prefilled autoinjectors or syringes |
Adult migraine prevention
AIMOVIG is US-labeled for preventive treatment of migraine in adults. It is a monoclonal antibody directed at the CGRP receptor. It does not supply an acute attack-treatment plan; the prescribing team should explain how prevention and any rescue medicine fit together.
Source: [1]
Check strength and injection device
The source lists 70 mg/mL and 140 mg/mL single-dose prefilled autoinjectors and syringes for injection under the skin. The label describes monthly administration. Training and the instructions for the supplied device are needed, including storage, preparation and disposal. Listed presentations do not prove that every device is currently available locally.
Source: [1]
Constipation can become serious
Constipation is a reported adverse reaction and the label warns about cases with serious complications. Severe or persistent constipation, especially with abdominal pain, vomiting or bloating, warrants prompt medical contact. Tell the clinician about other medicines that reduce bowel movement rather than managing a worsening problem without review.
Source: [1]
Allergy, blood pressure and circulation
Serious hypersensitivity reactions may be delayed, including more than a week after injection. Obtain urgent help for severe allergy symptoms. Hypertension and Raynaud's phenomenon can develop or worsen. Report blood-pressure increases and painful or discolored fingers or toes so the treating team can assess whether treatment should continue.
Source: [1]
Do not exchange antibody products by dose
Erenumab, fremanezumab and galcanezumab are different active medicines. Their strengths and devices do not provide an equivalence rule. Keep the exact brand, strength and administration date in the medicine record, and discuss tolerability or an intended change with the clinician before the next injection.
The AIMOVIG and AJOVY comparison provides a separate side-by-side reference, without establishing an individual treatment choice.
Source: [1]
Questions and answers
Does AIMOVIG target CGRP itself or its receptor?
Erenumab targets the CGRP receptor. This distinguishes its identity from antibodies directed at the CGRP ligand.
Why is constipation highlighted for AIMOVIG?
The label includes constipation with serious complications, beyond routine mild bowel symptoms.
Does this reference establish use in children?
No. The cited AIMOVIG indication is migraine prevention in adults.
Related reading
Sources
Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026